Stay updated on Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial
Sign up to get notified when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.

Latest updates to the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedPublications section saw minor wording changes: new sentences clarify voluntary publication notes and auto-fill from PubMed, and the revision tag was updated to v3.3.2 (replacing v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedThe government funding lapse notice banner was removed from the page; this banner previously provided general operating status information but does not affect the study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check33 days agoChange DetectedNo significant changes to the study page content are observable between the screenshots; only minor formatting/layout differences are present. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check62 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference2%

- Check69 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page version updated from v3.0.1 to v3.0.2. The Back to Top element was removed, with no changes to core content.SummaryDifference0.1%

Stay in the know with updates to Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.